Belvedere Trading’s Unity Biotechnology UBX Stock Holding History

Belvedere Trading’s Portfolio UBX Stock Details UBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-9	Closed	–	–	600
2021 Q2	$0	Buy	+9	New	+$433	﹤0.01%	443

Other funds holding UBX

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ECM

ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Belvedere Trading's UBX Position: Q3 2021 in Review

Belvedere Trading sold out of Unity Biotechnology (UBX) in Q3 2021, closing a stake of 9 shares.

Belvedere Trading first reported a position in UBX in Q2 2021 and held it in 1 quarter. The position peaked at $0 in Q2 2021. 84 funds tracked by Wall St. Rank hold UBX as of Q3 2021.

Belvedere Trading reported no remaining Unity Biotechnology position as of Q3 2021 after selling out during the quarter.
Belvedere Trading sold 9 Unity Biotechnology shares in Q3 2021.
Belvedere Trading first reported a position in Unity Biotechnology in Q2 2021 and held it in 1 quarter.
Belvedere Trading's Unity Biotechnology position peaked at $0 in Q2 2021.
84 funds tracked by Wall St. Rank held Unity Biotechnology as of Q3 2021.

Based on Belvedere Trading's 13F filing for Q3 2021, filed 19 Oct 2021.